Satralizumab-mwge

Class: Immunomodulatory Agents
Brands: Enspryng

Medically reviewed by Drugs.com on Sep 7, 2020. Written by ASHP.

Introduction

Satralizumab-mwge is an interleukin-6 (IL-6) receptor antagonist.

Uses for Satralizumab-mwge

Satralizumab-mwge has the following uses:

Satralizumab-mwge is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Satralizumab-mwge Dosage and Administration

General

Satralizumab-mwge is available in the following dosage form(s) and strength(s):

Injection: 120 mg/mL in a single-dose prefilled syringe.

Dosage

It isessentialthat the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Adults

Dosage and Administration

• Hepatitis B virus (HBV), tuberculosis, and liver transaminase screening is required before the first dose.

• Prior to every use, determine if there is an active infection.

• The recommended loading dosage of satralizumab-mwge is 120 mg by subcutaneous injection on weeks 0, 2, and 4, followed by a maintenance dosage of 120 mg every 4 weeks.

• See the manufacturer's labeling for important preparation and administration instructions.

Cautions for Satralizumab-mwge

Contraindications

• Known hypersensitivity to satralizumab or any of the inactive ingredients.

• Active HBV infection.

• Active or untreated latent tuberculosis.

Warnings/Precautions

Infections

An increased risk of infections, including serious and potentially fatal infections, has been observed in patients treated with IL-6 receptor antagonists, including satralizumab-mwge.

The most common infections reported in a randomized clinical trial of patients treated with satralizumab-mwge who were not on other chronic immunosuppressant therapies (Study 1), and that occurred more often than in patients receiving placebo, were nasopharyngitis (12%) and cellulitis (10%). The most common infections in patients who were on an additional concurrent immunosuppressant, and that occurred more often than in patients receiving placebo, were nasopharyngitis (31%), upper respiratory infection (19%), and pharyngitis (12%).

Delay satralizumab-mwge administration in patients with an active infection, including localized infections, until the infection is resolved.

HBV Reactivation

Risk of HBV reactivation has been observed with other immunosuppressant therapies. Pat...